Cystic Acne Market Overview
Cystic Acne Market Size was valued at USD 7.36 Billion in 2023. The Cystic Acne industry is projected to grow from USD 7.97 Billion in 2024 to USD 14.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.01% during the forecast period (2024 - 2032).
Cystic acne is the most serious type of acne, it is the type of skin condition wherein the pores of the skin get blocked, which leads to infection or inflammation of the affected area of the skin. Sometimes bacteria get trapped inside the pore and swell the infected skin area. It happens when the infection went deep into the skin and spread throughout the body. Although bacterium (P. acne bacteria) causes the cystic acne, which also causes papules, pustules, and such others, Cystic acne lesions are one of the most difficult acne to treat. These lesions are more painful and have a risk of scarring the skin and causing a permanent damage as compared to mild or moderate acne.
According to the American Academy of Dermatology Association, around 50 million Americans get affected annually with acne, and it is the most common skin condition in the Americas. Additionally, approximately 85% of people between the ages of 12 and 24 experience at least minor acne.
Rising prevalence of this conditions both in developed and developing countries is driving the cystic acne market growth. The skin care industry and research laboratories are involved in research and development to provide the better treatment. According to Leon H. Kircik, M.D., clinical associate professor of dermatology at Indiana University School of Medicine, recent research on severe and moderate acne patients with inflammatory acne helps to confirm the strength and efficacy of fixed-dose combination gel adapalene/benzoyl peroxide 0.3%/2.5%.
The factors that cause cystic acne are too much oil production in the glands of the skin and growth of the bacteria called Propionibacterium acnes. Moreover, advancing technology in healthcare is adding fuel to the growth of the market. However, effective treatments are not available in the market, which may hamper the market growth during the forecast period.
Intended Audience
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Figure: Global Cystic acne Market, By Region Market Share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
Cystic Acne Market Segment Insights
The global cystic acne market is segmented on the basis of causes, long-term effects, treatment type, and end user.
On the basis of the causes, it is segmented into hormonal imbalances, occlusive skin products, drugs/chemical side effects, and others.
On the basis of the long-term effects, it is segmented into ice pick scars, larger pits on the skin, shallow depressions, hypertrophic scarring, and others.
On the basis of the treatment type, it is segmented into topical medications, drainage & extraction procedure, laser therapy, microdermabrasion, and others.
On the basis of the end user, it is segmented into hospitals, clinics, research laboratories, and others.
Cystic Acne Market Regional Analysis
The Americas dominate the global cystic acne market owing to well-developed technology and increasing population with acne. Key players are focusing on capturing maximum share of the emerging markets such as India and China. According to American Academy of Dermatology Association, in 2016 the costs associated with the treatment of acne exceed USD 3 billion.
Europe holds the second position in the global cystic acne market owing to the government support for research & development and availability of funds for research. This is expected to drive the European cystic acne market over the forecasted period.
The Asia Pacific is the fastest growing cystic acne market owing to the presence of rapidly growing patient population, and high healthcare expenditure. The government of this region focuses more on providing better treatment to the citizen of their countries for improving their quality of life.
On the other hand, in the Middle East and Africa, cystic acne has become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Cystic Acne Market- Key Players
Some of the key players in this cystic acne market are
- GlaxoSmithKline plc (U.K)
- Pfizer Inc. (U.S.)
- Abbott Laboratories (U.S.)
- Hexal AG (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Alma Lasers Inc. (Israel)
- Bristol-Myers Squibb Company (U.S.)
- GE Healthcare (U.K)
- National Biological Corp. (U.S.)
- Herbert Waldmann GmbH & Co. KG (Germany)
- Sylvan Company (U.S.)
- DUSA Pharmaceuticals Inc. (U.S.)
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Report Attribute/Metric |
Details |
  Market Size |
  14.98 Billion |
  CAGR |
 9.01% |
 Base Year |
  2023 |
Forecast Period |
  2024-2032 |
Historical Data |
  2020 |
Forecast Units |
  Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Causes, long-term effects, treatment type, and end user. |
Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
  Key Vendors |
GlaxoSmithKline plc (U.K), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), Hexal AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Alma Lasers Inc. (Israel), Bristol-Myers Squibb Company (U.S.), GE Healthcare (U.K), National Biological Corp. (U.S.), Herbert Waldmann GmbH & Co. KG (Germany), Sylvan Company (U.S.), and DUSA Pharmaceuticals Inc. (U.S.) |
Key Market Opportunities |
Research and development |
Key Market Drivers |
Rising prevalence of this conditions both in developed and developing countries |
Cystic Acne Market Highlights:
Frequently Asked Questions (FAQ) :
Cystic acne market is projected to grow at a 9.01% CAGR during 2024-2032.
Key factors driving the cystic acne market growth include rising prevalence of cystic acne and technological advancements in healthcare.
Lack of effective treatment may limit the cystic acne market growth.
Major end users of cystic acne market include research laboratories, clinics, hospitals, and others.
Key players profiled in the cystic acne market include DUSA Pharmaceuticals Inc. (U.S.), Sylvan Company (U.S.), Herbert Waldmann GmbH & Co. KG (Germany), National Biological Corp. (U.S.), GE Healthcare (U.K), Bristol-Myers Squibb Company (U.S.), Alma Lasers Inc. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Hexal AG (Germany), Abbott Laboratories (U.S.), Pfizer Inc. (U.S.), and GlaxoSmithKline plc (U.K).